Abemaciclib

• TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of Vepdegestrant (ARV-471) in Combination With Other Medicines… Ended
  2022-502228-34-00 Phase I/II 2 countries Pfizer Inc.
• Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer wit… Ended
  2024-511209-49-00 Phase IV 1 country Universitaetsklinikum Ulm AöR
• Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer Ended
  2023-506771-10-00 Phase III 9 countries Eli Lilly & Co.
• A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended
  2023-503990-39-00 Phase III 12 countries AstraZeneca AB
• EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER… Ended
  2023-506786-63-00 Phase III 8 countries Eli Lilly & Co.
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tu… Ended
  2023-508194-89-00 Phase II 5 countries F. Hoffmann-La Roche AG
• Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-… Ended
  2023-504997-39-00 Phase III 8 countries AstraZeneca AB
• Clinical trial to compare efficacy and safety of standard chemotherapy versus letrozole plus abemaciclib, chosen randomly, as neoadjuvant th… Ended
  2024-514395-40-00 Phase II 1 country Fundacion Grupo Espanol De Investigacion En Cancer De Mama
• A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended
  2023-509242-35-00 Phase III 3 countries WSG Westdeutsche Studiengruppe GmbH
• Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, … Ended
  2024-513005-31-00 Phase III 1 country Unicancer
• A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Ended
  2023-506777-36-00 Phase II/III 6 countries Eli Lilly & Co.
• Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended
  2024-516204-42-00 Phase III 1 country BOOG Study Center B.V.
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended
  2023-509671-17-00 Phase III 16 countries Eli Lilly & Co.
• A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer Ended
  2023-507175-22-00 Phase II 1 country Eli Lilly & Co.
• A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER) Ended
  2023-506779-82-00 Phase III 1 country Eli Lilly & Co.
• A Study of abemaciclib Combined with Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Ended
  2023-506781-30-00 Phase III 5 countries Eli Lilly & Co.
• A Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Ewing's Sarcoma Ended
  2023-506772-28-00 Phase II 4 countries Eli Lilly & Co.
• A Phase 1b/2 Study of Abemaciclib Plus Chemotherapy and/or Chemoimmunotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory… Ended
  2023-506778-11-00 Phase I/II 1 country Eli Lilly & Co.
• Phase 1 / 2 study of amcenestrant (SAR439859) single agent and in combination with other anti-cancer therapies in postmenopausal women with … Ended
  2024-512997-89-00 Phase I (FiH) 2 countries Sanofi-Aventis Recherche & Developpement

Showing 25–43 of 43 trials